Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO).

Candoni A, Rambaldi A, Fanin R, Velardi A, Arcese W, Ciceri F, Lazzarotto D, Lussana F, Olivieri J, Grillo G, Parma M, Bruno B, Sora F, Bernasconi P, Saccardi R, Foà R, Sessa M, Bresciani P, Giglio F, Picardi A, Busca A, Sica S, Perruccio K, Zucchetti E, Diral E, Iori AP, Colombo AA, Tringali S, Santarone S, Irrera G, Mancini S, Zallio F, Malagola M, Albano F, Carella AM, Olivieri A, Tecchio C, Dominietto A, Vacca A, Sorasio R, Orciuolo E, Risitano AM, Leotta S, Cortelezzi A, Mammoliti S, Oldani E, Bonifazi F; GITMO.

Biol Blood Marrow Transplant. 2019 Dec;25(12):2388-2397. doi: 10.1016/j.bbmt.2019.07.037. Epub 2019 Aug 7.

PMID:
31400502
2.

Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.

Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MC, Bosi A, Russo D, Narni F, Messina G, Alessandrino EP, Carella AM, Milone G, Bruno B, Mammoliti S, Bruno B, Fanin R, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianti di Midollo Osseo. (GITMO).

Biol Blood Marrow Transplant. 2019 May;25(5):932-940. doi: 10.1016/j.bbmt.2018.12.064. Epub 2018 Dec 20.

PMID:
30579966
3.

Peritoneal carcinomatosis from ovarian paraganglioma: Report of a rare case and systematic review of the literature.

Bizzarri N, De Cian F, Di Domenico S, Centurioni MG, Mammoliti S, Ghirardi V, Vellone VG.

J Obstet Gynaecol Res. 2018 Sep;44(9):1682-1692. doi: 10.1111/jog.13713. Epub 2018 Jul 6.

PMID:
29978527
4.

NACT and laparoscopic-assisted radical vaginal trachelectomy in young patients with large (2-5 cm) high risk cervical cancers: Safety and obstetrical outcome.

Marchiolè P, Ferraioli D, Moran E, Mammoliti S, Tigaud JD, Beurrier F, Chopin N, Mathevet P.

Surg Oncol. 2018 Jun;27(2):236-244. doi: 10.1016/j.suronc.2018.04.006. Epub 2018 May 5. No abstract available.

PMID:
29937177
5.

Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report.

Giannelli F, Chiola I, Belgioia L, Garelli S, Pastorino A, Marcenaro M, Mammoliti S, Costantini S, Bizzarri N, Vellone V, Barra S, Corvò R.

J Contemp Brachytherapy. 2017 Dec;9(6):572-578. doi: 10.5114/jcb.2017.71554. Epub 2017 Dec 30.

6.

Steroid treatment of acute graft-versus-host disease grade I: a randomized trial.

Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, Sorasio R, Massi D, Van Lint MT, Raiola AM, Gualandi F, Selleri C, Sormani MP, Signori A, Risitano A, Bonifazi F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Haematologica. 2017 Dec;102(12):2125-2133. doi: 10.3324/haematol.2017.171157. Epub 2017 Sep 29.

7.

Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).

Marchetti C, Ferrandina G, Cormio G, Gambino A, Cecere S, Lorusso D, De Giorgi U, Bogliolo S, Fagotti A, Mammoliti S, Narducci F, Bergamini A, Scollo P, Biglia N, Breda E, Tamberi S, Marinaccio M, Angioli R, Salerno L, Eusebi MC, Loizzi V, Scambia G, Panici PB.

Gynecol Oncol. 2016 Dec;143(3):532-538. doi: 10.1016/j.ygyno.2016.09.025. Epub 2016 Oct 5.

PMID:
27717490
8.

[Burnout and risk of burnout in the teams of bone marrow transplant:<BR>a multicentre Italian survey].

Vagliano L, Ricceri F, Dimonte V, Scarrone S, Fiorillo L, Buono S, Del Giudice E, Conti F, Orlando L, Mammoliti S, Alberani F.

Assist Inferm Ric. 2016 Jan-Mar;35(1):6-15. doi: 10.1702/2228.24010. Italian.

PMID:
27183420
9.

Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement.

Ricci MT, Sciallero S, Mammoliti S, Gismondi V, Franiuk M, Bruzzi P, Varesco L.

Public Health Genomics. 2015;18(4):225-32. doi: 10.1159/000431352. Epub 2015 Jun 24.

PMID:
26111740
10.

Haemorrhagic cystitis in haematopoietic stem cell transplantation (HSCT): a prospective observational study of incidence and management in HSCT centres within the GITMO network (Gruppo Italiano Trapianto Midollo Osseo).

Gargiulo G, Orlando L, Alberani F, Crabu G, Di Maio A, Duranti L, Errico A, Liptrott S, Pitrone R, Santarone S, Soliman C, Trunfio A, Selleri C, Bruno B, Mammoliti S, Pane F.

Ecancermedicalscience. 2014 Apr 10;8:420. doi: 10.3332/ecancer.2014.420. eCollection 2014. Review.

11.

Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study.

Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, Mammoliti S, Matei D, Scambia G, Tonkin K, Shun Z, Sternas L, Spriggs DR.

Cancer. 2014 Feb 1;120(3):335-43. doi: 10.1002/cncr.28406. Epub 2013 Oct 11.

12.

Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?

Moioli M, Papadia A, Mammoliti S, Pacella E, Menoni S, Menada MV, Ragni N.

Minerva Ginecol. 2012 Apr;64(2):95-107. English, Italian.

PMID:
22481620
13.

Is magnetic resonance imaging useful in early evaluation of women on neoadjuvant chemotherapy for locally advanced cervical cancer?

Sala P, Marchiolè P, Cittadini G, Valenzano Menada M, Moioli M, Mammoliti S, Costantini S.

Eur J Gynaecol Oncol. 2012;33(1):31-6.

PMID:
22439402
14.

Pemetrexed disodium in ovarian cancer treatment.

Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, Ferrero S.

Expert Opin Investig Drugs. 2012 Apr;21(4):437-49. doi: 10.1517/13543784.2012.661714. Epub 2012 Feb 13. Review.

PMID:
22324304
15.

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.

Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, Buzenet G, Chamberlain D.

Gynecol Oncol. 2012 Apr;125(1):42-7. doi: 10.1016/j.ygyno.2011.11.021. Epub 2011 Nov 21.

PMID:
22112608
16.

Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB-IIA1).

Marchiole P, Tigaud JD, Costantini S, Mammoliti S, Buenerd A, Moran E, Mathevet P.

Gynecol Oncol. 2011 Sep;122(3):484-90. doi: 10.1016/j.ygyno.2011.05.010. Epub 2011 Jun 2.

PMID:
21636113
17.

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.

Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C.

Ann Oncol. 2011 Apr;22(4):973-8. doi: 10.1093/annonc/mdq436. Epub 2010 Sep 20.

18.

First-line single-agent cetuximab in patients with advanced colorectal cancer.

Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A.

Ann Oncol. 2008 Apr;19(4):711-6. Epub 2007 Dec 10.

PMID:
18073221
19.

Pemetrexed in gastric cancer.

Sobrero A, Caprioni F, Fornarini G, Mammoliti S, Comandini D, Baldo S, Decian F.

Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):51-5. Review.

20.

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.

Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest.

Cancer. 2004 Aug 15;101(4):704-12.

21.

Weekly paclitaxel in elderly patients with advanced breast cancer: a dose-finding study.

Repetto L, Comandini D, Mammoliti S, Pietropaolo M, Del Mastro L.

Drugs R D. 2004;5(1):11-5. No abstract available.

PMID:
14725485
22.

Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients.

Repetto L, Comandini D, Mammoliti S.

Crit Rev Oncol Hematol. 2001 Feb;37(2):147-52. Review.

PMID:
11166588
23.

Intraperitoneal carboplatin with or without interferon-alpha in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. G.O.N.O. Gruppo Oncologic Nord Ovest.

Bruzzone M, Rubagotti A, Gadducci A, Catsafados E, Foglia G, Brunetti I, Giannessi PG, Carnino F, Iskra L, Rosso R, Martoni A, Pannuti F, De Lisi V, Maltoni R, Ridolfi R, Mammoliti S, Gallo L, Boccardo F, Ragni N, Conte PF.

Gynecol Oncol. 1997 Jun;65(3):499-505.

PMID:
9190982
24.

Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.

Miglietta L, Amoroso D, Bruzzone M, Granetto C, Catsafados E, Mammoliti S, Guarneri D, Pedulla F, Foglia G, Ragni N, Martini MC, Brema F, Addamo G, Moraglio L, Pastorino G, Boccardo F.

Oncology. 1997 Mar-Apr;54(2):102-7.

PMID:
9075779
25.

Salvage chemotherapy with paclitaxel in platinum-resistant advanced ovarian cancer patients.

Bruzzone M, Catsafados E, Miglietta L, Amoroso D, Pedulla F, Giannessi PG, Locatelli MC, D'Antona A, Foglia G, Mammoliti S, Turno F, Gentile A, Nicosia F, Luporini G, Ragni N, Boccardo F.

Oncology. 1996 Sep-Oct;53(5):349-53.

PMID:
8784466
26.

High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.

Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G, Ragni N, Rosso R, Rugiati S, Rubagotti A.

J Clin Oncol. 1996 Feb;14(2):351-6.

PMID:
8636743
27.

Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients.

Mammoliti S, Merlini L, Caroti C, Gallo L.

Breast Cancer Res Treat. 1996;37(1):93-6.

PMID:
8750532
28.

Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.

Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Tixi LM, Bolli EA, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S, et al.

Clin Cancer Res. 1995 Sep;1(9):955-60.

29.

Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients.

Merlini L, Secondo V, Mammoliti S, Bellotti P, Castello C, Gallo L.

Anticancer Res. 1994 May-Jun;14(3B):1423-6.

PMID:
8067717
30.

Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients.

Mammoliti S, Merlini L, Caroti C, Gallo L.

Eur J Cancer. 1994;30A(2):248-9. No abstract available.

PMID:
8155400
31.

Cerebral metastases secondary to ovarian cancer: still an unusual event.

Bruzzone M, Campora E, Chiara S, Giudici S, Merlini L, Simoni C, Mammoliti S, Rubagotti A, Rosso R.

Gynecol Oncol. 1993 Apr;49(1):37-40.

PMID:
8482558
32.

The impact of received dose intensity on the outcome of advanced ovarian cancer.

Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C, Guido T, Conte PF, Campora E, Rubagotti A, et al.

Eur J Cancer. 1993;29A(2):181-4.

PMID:
8422279
33.

Clinical stage I and II endometrial carcinoma: multivariate analysis of prognostic factors.

Mammoliti S, Bruzzone M, Chiara S, Vidali A, Miglio L, Fontana V, Oliva C, Compora E, Giuntini P, Centonze M, et al.

Anticancer Res. 1992 Sep-Oct;12(5):1415-8.

PMID:
1444199
34.

Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.

Campora E, Oliva C, Mammoliti S, Cetto GL, Fosser V, Marangolo M, Rosso R.

Breast Cancer Res Treat. 1991 Oct;19(2):129-32.

PMID:
1836746
35.

Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience.

Chiara S, Mammoliti S, Oliva C, Merlini L, Bruzzone M, Sertoli MR, Parodi GC, Ragni N, Foglia G, Odicino F, et al.

Eur J Cancer. 1991;27(10):1211-5.

PMID:
1835588
36.

Crossover study with cisplatin or carboplatin in advanced ovarian cancer.

Repetto L, Chiara S, Mammoliti S, Guido T, Bruzzone M, Secondo V, Donadio G, Odicino F, Ragni N, Conte PF, et al.

Gynecol Oncol. 1990 Nov;39(2):146-9.

PMID:
2227588
37.

Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide.

Campora E, Vidali A, Mammoliti S, Ragni N, Conte PF.

Eur J Gynaecol Oncol. 1990;11(3):181-3.

PMID:
2209636
38.

Re-targeting of human lymphocytes expressing the T-cell receptor gamma/delta to ovarian carcinoma cells by the use of bispecific monoclonal antibodies.

Ferrini S, Prigione I, Mammoliti S, Colnaghi MI, Ménard S, Moretta A, Moretta L.

Int J Cancer. 1989 Aug 15;44(2):245-50.

PMID:
2527207
39.

Monoclonal antibodies which react with the T cell receptor gamma/delta recognize different subsets of CD3+WT31- T lymphocytes.

Ferrini S, Prigione I, Bottino C, Ciccone E, Tambussi G, Mammoliti S, Moretta L, Moretta A.

Eur J Immunol. 1989 Jan;19(1):57-61.

PMID:
2784109
40.

Retargeting of T-cell-receptor gamma/delta+ lymphocytes against tumor cells by bispecific monoclonal antibodies. Induction of cytolytic activity and lymphokine production.

Ferrini S, Prigione I, Mammoliti S, Colnaghi MI, Menard S, Moretta A, Moretta L.

Int J Cancer Suppl. 1989;4:53-5.

PMID:
2530184
41.

[Aprotinin-bupivacaine combination in the treatment of postoperative pain. Its effects on respiration and on resultant blood gas analysis parameters].

Barillà S, Catanzariti C, Mammoliti S.

Minerva Anestesiol. 1983 Mar;49(3):123-6. Italian. No abstract available.

PMID:
6190106

Supplemental Content

Loading ...
Support Center